U.S. Markets open in 2 hrs 49 mins

Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

Mike Benson
Sarepta Therapeutics’ Q2 2018 Earnings and Revenue Growth

Sarepta Therapeutics (SRPT), a commercial-stage biopharmaceutical company, develops unique RNA-targeted therapeutics, gene therapies, and other medicines for neuromuscular diseases. It released its Q2 2018 earnings on August 8 and surpassed Wall Street analysts’ estimates for EPS and revenues. It reported adjusted EPS of -$0.43 on revenues of $73.5 million compared to the estimated EPS of -$0.89 on revenues of $71.6 million.